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Abstract
Introduction We compared levels of protein and mRNA
expression of three members of the claudin (CLDN) family in
malignant breast tumours and benign lesions.
Methods Altogether, 56 sections from 52 surgically resected
breast specimens were analyzed for CLDN1, CLDN3 and
CLDN4 expression by immunohistochemistry. mRNA was also
analyzed using real-time PCR in 17 of the 52 cases.
Results CLDNs were rarely observed exclusively at tight
junction structures. CLDN1 was present in the membrane of
normal duct cells and in some of the cell membranes from ductal
carcinoma in situ, and was frequently observed in eight out of
nine areas of apocrine metaplasia, whereas invasive tumours
were negative for CLDN1 or it was present in a scattered
distribution among such tumour cells (in 36/39 malignant
tumours). CLDN3 was present in 49 of the 56 sections and
CLDN4 was present in all 56 tissue sections. However, CLDN4
was highly positive in normal epithelial cells and was decreased
or absent in 17 out of 21 ductal carcinoma grade 1, in special
types of breast carcinoma (mucinous, papillary, tubular) and in
areas of apocrine metaplasia. CLDN1 mRNA was
downregulated by 12-fold in the sample (tumour) group as
compared with the control group using GAPDH as the
reference gene. CLDN3 and CLDN4 mRNA exhibited no
difference in expression between invasive tumours and
surrounding tissue.
Conclusions The significant loss of CLDN1 protein in breast
cancer cells suggests that CLDN1 may play a role in invasion
and metastasis. The loss of CLDN4 expression in areas of
apocrine metaplasia and in the majority of grade 1 invasive
carcinomas also suggests a particular role for this protein in
mammary glandular cell differentiation and carcinogenesis.
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Introduction
In epithelial cells, tight junctions (TJs) are the most apical
intercellular junctions, and function as selective barriers to
macromolecules and prevent diffusion of lipids and pro-
teins between apical and basolateral membrane domains.
TJs appear as a network of continuous and anastomosing
filaments on the protoplasmic face of the plasma mem-
brane [1]. The molecular architecture of TJ strands has
been described in recent years. The proteins involved in the
formation of TJs have been divided into two categories:
integral membrane proteins, such as claudins (CLDNs),
occludins and JAM (junctional adhesion molecule) [2]; and
peripheral membrane proteins, such as zonulae occludens
(ZO)-1, ZO-2 and ZO-3, cingulin, symplekin, pilt, MAGI-1
(MAGUK [membrane associated guanylate kinase]
inverted protein 1) and AF-6 (afadin) [3].
CLDNs, a family comprising 24 members, are the main fam-
ily of proteins that make up the TJs [2,4]. The tightness of
individual TJ strands in situ is determined by the various
combinations of CLDN family members. CLDNs have a
membrane topology similar to that of occludin, even though
they are smaller proteins of about 22 kDa. Their protein
structure, which is uniform among family members,
CLDN = claudin; DCIS = ductal carcinoma in situ; GAPDH = glyceraldehyde-3-phosphate dehydrogenase; IDC = invasive ductal carcinoma; ILC = 
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contains four transmembrane domains with amino- and car-
boxyl-termini in the cytoplasm and two extracellular loops
[5].
Until now only few data have been reported regarding the
role played by CLDNs in breast lesions, and findings on
their function remain controversial [6,7]. There is 38%
homology between human CLDN1 and CLDN2 at the
amino acid sequence level [8,9]. Expression of the four-
exon CLDN1 gene, formerly named senescence associ-
ated epithelial membrane protein, was identified in testis
[10], colorectal carcinoma [11] and lung [12]. The direct
involvement of CLDN1 in the barrier function of TJs has
been demonstrated in CLDN1-over-expressing MDCK
cells [13].
In a study conducted in breast carcinomas by Kramer and
coworkers in 2000 [7] it was shown that there are no
genetic alterations in the promoter or coding sequences in
the CLDN1 gene that could account for the loss of CLDN1
protein expression in tumour cells. Of the relatively few
publications concerning CLDN expression in the breast,
one study [14] found that CLDN7 protein and mRNA are
downregulated in primary breast cancers as compared with
normal breast epithelium. Taken together, these observa-
tions indicate that there is a need to study the possible role
played by CLDNs in carcinogenesis and tumour
differentiation.
CLDN3 and CLDN4 can function as receptors for Clostrid-
ium perfringens enterotoxin [15]. The one-exon genes of
CLDN3 and CLDN4 are closely linked (CLDN3 7q11 and
CLDN4 7q11.23) and share extended homology of approx-
imately 80% at the DNA level. SAGE (serial analysis of
gene expression) demonstrated that, of differentially upreg-
ulated mRNAs, CLDN3 and CLDN4 were among the six
most upregulated in primary ovarian carcinoma cells [16].
Van Itallie and coworkers [17] demonstrated the close cor-
relation between the level of CLDN4 expression and
change in both conductance and ionic selectivity.
Thus far there is no evidence on how CLDN3 and CLDN4
are expressed in breast carcinomas. The present study was
designed to determine whether human CLDN1, CLDN3
and CLDN4 are expressed in different types of breast
lesions, what differences there are between different
CLDNs in breast, and how the protein expression corre-
lates with CLDN mRNA expression.
Methods
Materials
For immunohistochemistry, paraffin-embedded sections
were used. For immunofluorescence, paraffin-embedded
sections and frozen resected breast tissue samples were
analyzed. For real-time PCR RNA isolated from frozen sur-
gical breast tissues were analyzed.
Materials used for immunohistochemistry
Altogether, 56 paraffin-embedded sections from 52 surgi-
cally resected breast specimens were analyzed for expres-
sion of CLDN1, CLDN3 and CLDN4 using
immunohistochemistry. Tissue samples were collected with
the patient's written consent and conforming with national
law (23/2002.V.9 EüM) regarding human studies. The age
of the 52 female patients ranged between 31 and 80 years.
Carcinomas were graded according to the Elston-Bloom
and Richardson system [18].
The histopathological diagnoses of the selected breast
lesions were as follows: fibrocystic changes/breast lesions
(n = 12), ductal carcinoma in situ (DCIS; n = 5), invasive
ductal carcinoma (IDC) ± DCIS (n = 27), invasive lobular
carcinoma (ILC; n = 5) and special types of breast carci-
noma (papillary, mucinous, tubular; n = 7).
Materials used for immunofluorescene
Immunofluorescence detection of CLDN1, CLDN3 and
CLDN4 was performed on frozen sections (IDC and sur-
rounding breast) as well as on tissue microarray of IDCs
obtained from paraffin-embedded blocks.
Materials used for CLDN1, CLDN3, CLDN4 and GAPDH 
mRNA expression with real-time PCR
In 17 out of the 52 cases analyzed by immunohistochemis-
try, the level of mRNA expression of CLDN1, CLDN3 and
CLDN4 were also analyzed using real-time PCR. The his-
topathological diagnoses of these 17 breast lesions are as
follows: fibrocystic changes/breast lesions (n = 3), IDC ±
DCIS (n = 12), ILC (n = 1) and intraductal papilloma (n =
1). In the following text only the real-time PCR results for
the 13 invasive carcinomas (12 IDC ± DCIS and 1 ILC) are
discussed in detail.
Because relative quantification of the real-time PCR results
was used for data analyses in all 17 breast samples, the
normal component of the breast tissue was simultaneously
investigated for mRNA expression of CLDN1, CLDN3,
CLDN4 and glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) mRNA expression. GAPDH was used as the ref-
erence gene, and so data are normalized to GAPDH.
Breast tissue samples, obtained in accordance with current
local and ethical recommendations, were snap frozen in liq-
uid nitrogen within 30 min of surgical removal and stored at
-80°C.Available online http://breast-cancer-research.com/content/7/2/R296
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Immunohistochemistry for CLDN1, CLDN3 and CLDN4 
detection
Immunohistochemical detection of CLDNs was performed
in formalin-fixed, paraffin-embedded sections. Sections (5
µm thick) were cut from each paraffin block, deparaffinized
and rehydrated. Immunohistochemical staining for CLDN1,
CLDN3 and CLDN4 was performed using the streptavidin-
peroxidase procedure.
For CLDN1 and CLDN3 proteins, antigen retrieval was per-
formed with two different antigen retrieval solutions in par-
allel sections: 20 min in Vector (Burlingame, CA, USA)
antigen retrieval solution in a microwave oven; and 40 min
in DAKO (Carpinteria, CA, USA) antigen retrieval solution
in a microwave oven. For CLDN4, antigen retrieval was per-
formed for 20 min in Vector antigen retrieval solution in a
microwave oven. Endogenous peroxidase was blocked
with 1% H2O2 for 10 min at room temperature.
Sections were incubated with primary antibodies (Zymed,
San Francisco, CA, USA) to CLDN1, CLDN3 and CLDN4
(concentration 1:100) overnight. The antibodies used were
polyclonal rabbit anti-CLDN-1 (Zymed; reactivity: human,
rat and dog), polyclonal rabbit anti-CLDN-3 (Zymed; reac-
tivity: human, mouse and dog) and monoclonal mouse anti-
CLDN-4 (Zymed; reactivity: human).
Antigen-bound primary antibody was detected using stand-
ard avidin–biotin immunoperoxidase complex (DAKO
LSAB2 Kit). The chromogen substrate was aminoethylcar-
bazol. In each case, for counter-staining Mayer's hae-
malaun was used. For each CLDN a negative control with
omission of the primary antibody was included. Colon car-
cinoma was used as positive control. In each case, two
independent observers (A-MT and JK) recorded the distri-
bution of staining, intensity and localization. Staining of
CLDNs was expressed relative to adjacent normal mam-
mary epithelium.
Immunofluorescence microscopy for CLDN1, CLDN3 and 
CLDN4 detection
Sections (10 µm thick) were cut from frozen tissue and
from breast tissue array paraffin blocks. The tissue arrays
were constructed in our laboratory. The selected breast
tumour samples were obtained from paraffin blocks from
our files. In brief, the study involved breast tumours from 30
T1N0 and 30 T1N1 cases. Histopathological data included
tumour stage according to the UICC TNM system. With the
guidance of an experienced pathologist (JK), representa-
tive core tissue biopsies (2 mm in diameter) were taken
from archival paraffin-embedded primary breast carcino-
mas and seeded in new paraffin blocks using an instrument
provided by Histopathology Company (Pécs, Hungary).
Two biopsies were taken from each paraffin block. For par-
affin-embedded sections antigen retrieval was performed
as described above (under Immunohistochemistry for
CLDN1, CLDN3 and CLDN4 detection).
Sections were incubated with goat antiserum for 1 hour at
room temperature and then incubated with the primary anti-
bodies (Zymed) to CLDN1, CLDN3 and CLDN4 (1:50)
overnight. CLDN1 and CLDN3 antigen-bound primary anti-
body was detected using anti-rabbit IgG conjugated to
Alexafluor 488 (Molecular Probes, Eugene, OR, USA) and
CLDN4 stained sections was detected using anti-mouse
IgG conjugated to Alexafluor 488 (Molecular Probes) for
30 min at room temperature. Cell nuclei were counter-
stained with propidium iodide (Molecular Probes) for 10
min at room temperature. For each CLDN a negative con-
trol with omission of the primary antibody was included.
Coverslips were mounted with fluorescent mounting
medium (DAKO). Stained specimens were analyzed by
laser scanning confocal microscopy (MRC 1024; Bio-Rad,
Hercules, CA, USA).
Western blotting
The monospecificity of CLDN1, CLDN3 and CLDN4 anti-
bodies was tested by our group in whole tumour cell lysate
by Western blot analyses, as described previously [14]. In
brief, from snap frozen tissues of IDC of the breast and nor-
mal tissue surrounding the tumour, total protein was
extracted using lysis buffer (100 mmol/l NaCl, 1% NP-40,
2 mmol/l EDTA, 50 mmol/l TRIS, 20 µg/ml aprotinin, 20 µg/
ml leupeptin, 1 mmol/l PMSF, pH 7.5). Subsequently, the
samples were mixed with 2× Laemmli sample buffer and
boiled for 10 min, followed by centrifugation at 13,000 rpm
for 15 min. Similar amounts of protein were loaded in each
lane and run on 10% SDS-PAGE under reducing condi-
tions. Then, gel electrophoresis proteins were transferred
to nitrocellulose membranes. For immunodetection, blots
were incubated with CLDN1 polyclonal antibody (1:400),
CLDN3 polyclonal antibody (1:800) and CLDN4 mono-
clonal antibody (1:200) overnight. The biotinylated second-
ary antibody, goat anti-mouse IgG (diluted 1:2000, E433;
DAKO), was applied for 1 hour at room temperature. Anti-
body detection was conducted using an enhanced chemi-
luminescent reaction system.
Real-time PCR for CLDN1, CLDN3, CLDN4 and GAPDH 
mRNA detection
RNA isolation
Breast tissue (50–100 mg) was homogenized and RNA
was isolated with Trizol (Invitrogen, Carlsbad, CA, USA)
[19], in accordance with the manufacturer's instructions,
using a Polytron homogenizer (Kinematica AG, Littau/
Lucerne, Switzerland). Briefly, the RNA was precipitated
with 0.5 ml isopropyl alcohol in the aqueous phase. The
RNA pellet was washed once in 70% ethanol, dried and
resuspended in 50 µl of RNAse-free water and kept at -
80°C until use. Total RNA integrity was verified byBreast Cancer Research    Vol 7 No 2    Tőkés et al.
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electrophoresis using ethidium bromide staining as well as
by measuring optical density (OD). OD 260 nm/OD 280
nm absorption ratio was accepted between 1.70 and 2.8.
Reverse transcription of RNA
Total RNA (700 ng) was reverse transcribed for 40 min at
48°C in 30 µl with 2.5 unit M-MuLV reverse transcriptase
(Applied Biosystems, Foster City, CA, USA) in the pres-
ence of RNAse inhibitor (Applied Biosystems) using Ran-
dom Hexamers (Applied Biosystems).
Real-time PCR
Conditions for real-time PCRs were optimized in a gradient
cycler (Mastercycler Gradient, Eppendorf, Hamburg, Ger-
many). Optimized conditions were transferred to the Bio-
Rad real time PCR detection system as follows. Typical
real-time PCR reaction was conducted with 2 µl cDNA
template in a total volume of 25 µl, using the Bio-Rad iCy-
cler Real Time PCR detection system (BioRad 1708740).
For CLDNs and GAPDH the SYBR Green based real-time
PCR method was used. Each PCR was conducted in 25 µl
volume of 1 × PCR puffer (BioRad 1708882) with 300
nmol/l of each primer (Table 1) for 2 min at 95°C for initial
denaturing, then 40 cycles of 95°C for 20 s, 63°C for 30 s,
and 72°C for 30 s, followed by melting analyses from 55 to
95°C. Melting curve analyses resulted in single product
specific melting temperatures for the analyzed CLDN1,
CLDN3, CLDN4 and GAPDH genes. No primer–dimer for-
mations were observed during the 40 real-time PCR ampli-
fication cycles. PCR reaction for each sample was done in
duplicate in 96-well plates. In addition, the resulting real-
time PCR product (10 µl) was loaded onto 2% agarose gel
prepared in Tris-borate EDTA puffer and stained with ethid-
ium bromide (Bio-Rad). Each PCR was optimized to ensure
that no bands corresponding to genomic DNA amplifica-
tion or primer–dimer pairs were present. The relative quan-
tification method (described in detail by Pfaffl and
coworkers [20] from the Technical University of Munich)
was used for data analysis of real-time PCR. The program
included a statistical evaluation. Data were analyzed for sig-
nificant differences by analysis of variance using approxi-
mate tests [20]. The relative expression is based on the
expression ratio of a target gene versus a reference gene
(GAPDH).
Electron microscopy
In two cases both the normal breast tissue and the tumour
sample were investigated by transmission electron micros-
copy in order to analyze the presence of TJs in tumours
compared with nontumourous tissue, as described previ-
ously [21].
Results
Immunohistochemical localization of CLDNs indicated that
CLDNs were expressed along the entire length of the lat-
eral plasma membranes between epithelial cells, including
apical areas containing TJ structures. Using electron micro-
scopy, TJ structures were identified in normal breast as well
as in breast tumour tissue. Cell types in breast tissue are
heterogeneous, and it is therefore noteworthy that CLDNs
were expressed only in epithelial cells. Surrounding fibrob-
lasts and adipocytes served as negative controls because
these cells were negative for CLDN antibodies.
Immunohistochemistry of CLDN1
The two antigen retrieval methods used yielded similar
results. The monospecificity of the CLDN antibodies was
tested by Western blot analyses, and a single band was
found at approximately 20 kDa for CLDN1, CLDN3 and
CLDN4 (Fig. 1).
Immunohistochemical localization of CLDN1 indicated that
CLDN1 was present in the membranes of normal duct cells
in the majority of cases (Fig. 2a). CLDN1 positivity was also
observed in some cell membranes in pure DCIS cases or in
the DCIS component of invasive carcinomas. On the other
hand, major differences in CLDN1 expression were
observed among tumours.
Two major differences were noticed. First, in 36 of the 39
carcinomas examined, invasive tumour cells were either
negative for CLDN1 or it was present in a scattered distri-
Table 1
The CLDN1, CLDN3, CLDN4 and GAPDH primer sequences, position and product size
Primer Forward Reverse Product size 
(bp)
GI number
Sequence 5'–3' Size (bp) Sequence 5'–3' Size (bp)
CLDN1 ttcgtacctggcattgactgg 378–399 22 ttc gta cct ggc att gac tgg 470–490 21 112 4559277
CLDN3 ctgctctgctgctcgtgtcc 732–751 20 ttagacgtagtccttgcggtcgtag 836–860 25 128 21536298
CLDN4 ggctgctttgctgcaactgtc 741–761 21 gagccgtggcaccttacacg 829–848 20 107 14790131
GAPDH gaagatggtgatgggatttc 81–98 20 gaaggtgaaggtcggagt 287–306 18 225 7669491
bp, base pairs; CLDN, claudin; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.Available online http://breast-cancer-research.com/content/7/2/R296
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bution among such tumour cells (Fig. 2b). These findings
were confirmed by confocal microscopy images (Fig. 2c).
There was no difference immunohistochemically in CLDN1
expression between different types of invasive carcinomas
or between ductal carcinomas of different grade. The sec-
ond major difference from normal tissue was that CLDN1
was frequently present (eight out of nine samples) in areas
of apocrine metaplasia (Fig. 2d). In these cases positivity
was observed only in cells of apocrine metaplasia, and the
neighbouring tumour tissue was negative for CLDN1.
Immunohistochemistry of CLDN3 and CLDN4
CLDN3 positivity was observed in the majority (49/56) of
cases examined (12 fibrocystic breasts, 5 DCIS, 23 IDC, 4
ILC, 2 mucinous, 2 tubular and 1 papillary breast carcino-
mas) and in all cases analyzed by confocal microscopy.
There were no remarkable differences in CLDN3 expres-
sion in different types of breast lesions or between normal
and tumour components (Fig. 3a,b). CLDN3 expression is
evaluable by standard immunohistochemistry and by com-
paring two antigen retrieval methods; in the majority of
cases CLDN3, similar to CLDN1, was observed along the
entire length of the epithelial cell membrane, but in a few
cases, especially in normal tissues and in tissue with fibro-
cystic changes, CLDN3 appeared to be localized close to
the apical end of the cells or at the basolateral membrane
of the epithelial cells. These findings were seen on both
confocal and light microscopy (Fig. 3c,d).
CLDN4 positivity was present in all 56 tissue sections in
epithelial cell membranes as well as in the frozen section
and breast tumour array analyzed by confocal microscopy.
Intense positivity was observed in normal epithelial cells
(Fig. 4a) and in tumours of grade 2 and grade 3 (Fig. 4b),
and was greatly reduced in the majority of tumours of grade
1.
CLDN4 was absent or its expression was greatly reduced
in tumour cells of 17 out of 21 grade 1 tumours (Fig. 4c),
but it was present in the normal epithelial components
within the same blocks (14 IDC NST [no special type], 5
special types, 2 ILC). Positivity was seen in 8 out of 11
grade 2 tumours and in 5 out of 7 grade 3 invasive carcino-
mas. In the normal tissue surrounding grade 2 and 3
tumours, the CLDNs were consistently present. CLDN4
was absent or its expression was decreased in the seven
special-type breast carcinomas (mucinous, tubular, papil-
lary) but it was present in the normal tissue surrounding
these tumours. In contrast to CLDN1, CLDN4 was consist-
ently absent in regions of apocrine metaplasia (Fig. 4d).
Real time-PCR results
Real-time PCR using CLDN1, CLDN3, CLDN4 and
GAPDH specific primers was performed in the 17 samples
detailed above. mRNA was expressed in all of the analyzed
cases. Relative quantification using GAPDH as the refer-
ence gene was applied [20]. mRNA expression in 13
invasive tumours out of the 17 samples was analyzed as the
sample group, and the surrounding breast tissue was used
as the control group. During the real-time PCR reaction,
CLDN1 mRNA was detected in 12 out of 13 analyzed
tumours and in 12 out of 13 corresponding surrounding
nontumourous breast tissue samples. In normal, surround-
ing breast tissue, the mean value of crossing points (cycle
threshold) was 34,02 whereas in the tumour tissue sam-
ples it was 36,22 (indicating low levels of CLDN1 mRNA).
CLDN1 was downregulated by 12-fold in the sample
(tumour) group in comparison with the control group using
GAPDH as the reference gene. CLDN3 mRNA was
present in all tumours and surrounding tissues. CLDN3
exhibited no expressional difference between invasive
tumours and nontumourous tissue samples.
CLDN4 mRNA was also found to be present in these 13
invasive tumours and surrounding mammary tissues using
real time-PCR. According to relative quantification, CLDN4
mRNA expression did not appear to be changed in the inva-
sive tumours in comparison with the surrounding normal tis-
sue. It is important to emphasize that there were only two
Figure 1
The monospecificity of claudin (CLDN)4 antibody using Western blot  analysis The monospecificity of claudin (CLDN)4 antibody using Western blot 
analysis. CLDN4 protein expression in invasive breast carcinoma, sur-
rounding normal breast and human liver. Western blot analysis was per-
formed on equal amounts of protein from total cell lysates using CLDN4 
monoclonal antibody. A single band was shown at approximately 22 
kDa for CLDN4. IDC, invasive ductal carcinoma.Breast Cancer Research    Vol 7 No 2    Tőkés et al.
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grade 1 invasive tumour samples among the 13 investi-
gated invasive tumours.
The program used by us and described by Pfaffl and cow-
orkers [20] (Relative Expression Software Tool [REST] for
group-wise comparison and statistical analysis of relative
expression results in real-time PCR) includes a statistical
analysis (analysis of variance). Using this program, we
found no statistically significant differences in the distribu-
tion of data between the sample and control groups in
terms of CLDN expression (the P  values for CLDN1,
CLDN3 and CLDN 4 were 0.166, 0.928 and 0.996,
respectively). However, only 13 tumours were analyzed for
RNA expression using real-time PCR because fresh tumour
tissue and corresponding normal tissue surrounding the
tumour were available in only 13 cases. In these cases the
results of immunohistochemistry and real-time PCR
appeared to correlate; specifically, CLDN1 appeared to be
downregulated in tumours as compared with normal
breast, whereas CLDN3 was expressed at similar levels in
tumours and normal breast.
In the case of CLDN4 expression the differences observed
by immunohistochemistry between tumours of different
grade were not observed by real-time PCR. CLDN4 mRNA
expression did not appear to be changed in the invasive
tumours in comparison with the surrounding normal tissue.
Real-time PCR remains to be performed in a greater
number of cases, including tumours of different grade.
Apart from melting analysis, the specificity of real-time PCR
results was confirmed on 2% agarose gel electrophoresis.
The PCR product was seen at the appropriate size and
nonspecific bands were not visualized. The specificity of
real-time PCR of CLDN4 was also analyzed by sequencing
(data not shown).
Figure 2
Claudin (CLDN)1 positivity in normal breast epithelium, tumour cell membranes and intraductal papilloma Claudin (CLDN)1 positivity in normal breast epithelium, tumour cell membranes and intraductal papilloma. (a) CLDN1 positivity in normal breast epi-
thelium. Normal epithelial cells exhibit intensive CLDN1 positivity in the cell membrane. Image obtained using laser scanning confocal microscopy 
(MRC 1024; Bio-Rad). Primary antibody was CLDN1 polyclonal antibody (Zymed); secondary antibody was IgG conjugated to Alexafluor 488 
(Molecular Probes). Cell nuclei were counter-stained with propidium iodide. Green fluorescence along the cell membranes corresponds to CLDN1; 
the nuclei are seen in red. (Original magnification: 400×.) (b) CLDN1 positivity in tumour cell membranes. Shown is the immunohistochemical reac-
tion of invasive ductal carcinoma of the breast using polyclonal CLDN-1 antibody. Note the membrane staining only in some scattered tumour cells, 
as compared with normal epithelial cells (panel a). Sections were counter-stained with Mayer's haemalaun. The chromogen substrate was ami-
noethylcarbazol. (Original magnification: 600×.) (c) CLDN1 positivity in tumour cell membranes. Shown is the immunohistochemical reaction of inva-
sive ductal carcinoma using polyclonal CLDN1 antibody. There is scattered membrane staining in some tumour cells. The secondary antibody is IgG 
conjugated to Alexafluor 488. Cell nuclei were counter-stained with propidium iodide. The image was obtained using laser scanning confocal micro-
scopy (MRC 1024; Bio-Rad). (Original magnification: 400×.) (d) CLDN1 positivity in intraductal papilloma. Shown is the immunohistochemical reac-
tion of a breast papilloma with an area of apocrine metaplasia. There is increased CLDN1 positivity in apocrine cells and negative staining in the 
surrounding papilloma. Sections were counter-stained with Mayer's hemalaun. The chromogen substrate was aminoethylcarbazol. (Original magnifi-
cation: 200×.)Available online http://breast-cancer-research.com/content/7/2/R296
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Discussion
In the present study we examined the expression in breast
lesions of three members of the CLDN family, namely
CLDN1, CLDN3 and CLDN4. The majority of studies pub-
lished to date have described roles for CLDNs in forming
TJs [22], conferring ionic selectivity [17] and functioning as
a barrier [23], but only few data have been published on the
expression of CLDNs in the breast [14]. CLDN1 and
CLDN2 were the first described CLDN components of TJs,
and so the majority of data are related to these proteins. It
was demonstrated that CLDN1 and CLDN2 function as
major structural components of TJ strands, and that occlu-
din is an accessory protein within this structure [8,24].
Well developed TJs found in the lung contain CLDN3,
CLDN4 and CLDN5, which are abundant, whereas levels
of expression of CLDN1 and CLDN2 are reduced [12].
These findings suggest that different members of the
CLDN family are involved in the formation of TJ strands in
different tissues. The extent to which CLDN expression is
tissue dependent remains a subject of research interest, as
does the physiological relevance of the existence of multi-
ple CLDN species. In CLDN1-, CLDN2- and CLDN3-trans-
fected mouse L-cells, Kubota and coworkers [25] showed
that CLDNs may act as calcium-independent adhesion
molecules, although the adhesion strength is low. It was
hypothesized by Rangel and coworkers [26] that the pre-
cise ratio of different CLDNs determined the permeability
of TJs. In ovarian tumours, the same group suggested that
CLDN3 and CLDN4 are required for signalling through sur-
vival or proliferative pathways.
In the present study, immunohistochemistry revealed
expression of CLDNs in TJs along the lateral plasma mem-
branes of epithelial cells and along the basal plasma mem-
brane of the epithelium, suggesting that CLDNs are not
exclusively localized to TJs. Localization of these three
CLDNs together in breast tissue sections has not previ-
ously been reported, but based on the observations pre-
sented here CLDN1, CLDN3 and CLDN4 are not
Figure 3
Claudin (CLDN)3 positivity in benign breast tissue and invasive ductal breast carcinoma Claudin (CLDN)3 positivity in benign breast tissue and invasive ductal breast carcinoma. (a) CLDN3 positivity in benign breast tissue. Regular immu-
nohistochemical reaction of benign breast epithelial cells using polyclonal CLDN3 antibody. Continous membrane staining characterizes most of the 
luminal epithelial cells. Sections were counter-stained with Mayer's haemalaun. The chromogen substrate was aminoethylcarbazol. (Original magnifi-
cation: 400×.) (b) CLDN3 positivity in invasive ductal breast carcinoma. CLDN3 positivity is apparent in the membranes of some carcinoma cells. 
Sections were counter-stained with Mayer's hemalaun. The chromogen substrate was aminoethylcarbazol. (Original magnification: 600×.) (c) 
CLDN3 positivity in benign breast epithelium. CLDN3 positivity is seen in the majority of the membranes of benign epithelial cells. CLDN3 appeared 
to be localized in normal breast close to the apical end of the cell membranes or in the basolateral membranes of the epithelial cells. The primary anti-
body was CLDN3 polyclonal antibody (Zymed); the secondary antibody was IgG conjugated to Alexafluor 488 (Molecular Probes). Cell nuclei were 
counter-stained with propidium iodide. The image was obtained using laser scanning confocal microscopy (MRC 1024; Bio-Rad). (Original magnifi-
cation: 400×.) (d) CLDN3 positivity in benign breast epithelium. CLDN3 positivity is seen in the membranes of the majority of breast epithelial cells. 
The positive membrane reaction is incomplete in most of the cells. The primary antibody was CLDN3 polyclonal antibody (Zymed). Sections were 
counter-stained with Mayer's haemalaun. The chromogen substrate was aminoethylcarbazol. (Original magnification: 400×.)Breast Cancer Research    Vol 7 No 2    Tőkés et al.
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exclusively localized to areas of TJs. Gregory and cowork-
ers [27] described similar observations for CLDN1 in the
rat epididymis.
We demonstrated that immunohistochemically detectable
CLDN1 protein is absent or its expression is markedly
decreased in the majority of different types of invasive
breast carcinomas as compared with normal ducts. Of 39
malignant tumours examined by immunohistochemistry, 36
were negative for CLDN1 or it was present in a scattered
distribution among the tumour cells. CLDN1 mRNA
expression investigated by real-time PCR confirmed this
finding. The mRNA level in tumour is considerably lower
than that in normal breast tissue. Theoretically, several reg-
ulatory pathways could influence CLDN1 protein synthesis
and expression. How these regulatory pathways are
involved in cellular transformation and oncogenic progres-
sion in the breast remains to be elucidated. Previous stud-
ies reported that CLDN1 mRNA expression is absent or
downregulated in the majority of breast cancer cell lines
[28]. Kramer and coworkers [7] found no evidence for alter-
ations in the CLDN1 gene being responsible for the loss of
expression of CLDN1 protein. The same group found a sim-
ilar loss of CLDN1 expression in five primary breast
tumours. This finding is in contrast to the broad spectrum
of CLDN1 expression found in other human tissues, such
as liver and pancreas (our unpublished data). This may sug-
gest that CLDN1 might be involved in the development of
breast cancer or other epithelial tumours [7]. Whether TJs
are simply lost in breast neoplasia and whether downregu-
lation of CLDN1 is among the causative factors in this proc-
ess are unknown. Alterations in the number, appearance
and permeability of TJs have been described in various
tumour types [21,29]. Abnormalities in TJ permeability and
number greatly influence the transepithelial flux of growth
factors [30] and hence the development of epithelial
tumours [31]. In two cases, both normal breast tissue and
tumour sample were investigated by transmission electron
microscopy. Membrane densities corresponding to TJ
structures were identified in both normal and neoplastic
epithelial cells. The eventual abnormalities of TJs in breast
tumours must be analyzed in a large series of breast
tumours.
Figure 4
Claudin (CLDN)4 expression in benign breast epithelium, in invasive ductal carcinomas and in intraductal papilloma Claudin (CLDN)4 expression in benign breast epithelium, in invasive ductal carcinomas and in intraductal papilloma. (a) Intense CLDN4 positivity in 
benign breast epithelium. Shown is the immunohistochemical reaction of benign breast using monoclonal CLDN4 antibody (Zymed). Strong positiv-
ity is seen in epithelial cell membranes. Sections were counter-stained with Mayer's haemalaun. The chromogen substrate was aminoethylcarbazol. 
(Original magnification: 400×.) (b) CLDN4 positivity in invasive ductal breast carcinoma. CLDN4 is expressed in invasive ductal breast carcinoma of 
grade 3. Positive reaction is evident in the membranes of the tumour cells. Sections were counter-stained with Mayer's haemalaun. The chromogen 
substrate was aminoethylcarbazol. (Original magnification: 600×.) (c) CLDN4 expression in invasive ductal carcinoma of the breast. Shown is com-
plete loss of CLDN4 expression in invasive ductal breast carcinoma of grade 1 as compared with grade 3 (panel b). Sections were counter-stained 
with Mayer's haemalaun. The chromogen substrate was aminoethylcarbazol. (Original magnification: 400×.) (d) CLDN4 positivity in intraductal pap-
illoma. Shown is the immunohistochemical reaction of breast papilloma with an area of apocrine metaplasia. The loss of CLDN4 positivity in apocrine 
cells and the positive staining of other epithelial cells is a 'mirror image' of that seen in the CLDN1 reaction (Fig. 2d). Sections were counter-stained 
with Mayer's haemalaun. The chromogen substrate was aminoethylcarbazol. (Original magnification: 400×.)Available online http://breast-cancer-research.com/content/7/2/R296
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Although the similar CLDN3 and CLDN4 TJ proteins are
highly expressed in breast neoplasia, we hypothesize that
mechanisms other than alteration in TJs are involved in the
loss of CLDN1 expression in breast tumours. The role
played by CLDN1 positivity in apocrine cells observed in
this study requires further investigation. In the present
study, CLDN3 appeared to be expressed in a similar man-
ner in primary breast cancers as in normal epithelium.
Immunohistochemistry and real-time PCR yielded similar
findings without notable upregulation or downregulation in
different groups of tumours or compared with normal epi-
thelium. In the majority of cases, CLDN3 was found to be
localized along the entire membrane of epithelial cells, but
in some cases it was only detected close to the apical end
or at the basolateral membrane of the epithelial cells.
Although this observation was confirmed by both light and
confocal microscopy, in the breast this staining pattern has
not previously been reported. Interestingly, Rangel and
coworkers [26] did not find CLDN3 exclusively at the mem-
brane in any of the samples studied; the majority of samples
of primary ovarian tissue exhibited a combination of cyto-
plasmic and membrane staining. In gut, Rahner and
coworkers [32] found CLDN3 to be strongly expressed in
the surface epithelial cells of the stomach fundus, and have
found it to be distributed predominantly along the basola-
teral membrane and not at the TJ. That group concluded
that CLDNs have different patterns of expression in differ-
ent gastrointestinal tissues – patterns that should account
for differences in paracellular permeability.
We found that CLDN4 protein expression was downregu-
lated in grade 1 IDCs. Further sample collection and analy-
sis are required to confirm this result at the mRNA level,
because only two grade 1 IDCs were available for PCR
examination in our series. However, mRNA and protein
were expressed in grade 2 and 3 IDCs to degrees similar
to expression in surrounding breast tissue. In a study con-
ducted in ovarian tissue, Hough and coworkers [16] found
that expression of CLDN3 and CLDN4 protein was unde-
tectable in normal ovarian cells and highly expressed on the
membranes of ovarian carcinoma cells. Contrary to the find-
ings in ovarian tumours reported by Rangel and coworkers
[26] that CLDN3 and CLDN4 exhibited cytoplasmic stain-
ing and that over-expression of these proteins were associ-
ated with malignancy, in our study in breast we did not
observe clear positivity of CLDNs in cytoplasm. A close
relation between CLDN4 expression and changes in both
conductance and ionic selectivity has been described. Fur-
ther important observations were reported by van Itallie and
coworkers [17]; they found that the number of junction
strands was increased by over-expression of CLDN4, and
that the levels of several other strand proteins were unaf-
fected. Loss of CLDN4 from the cell surface coincides with
dramatic changes in the morphology of TJ fibrils. Removal
of CLDN4 disrupts fibril organization and increases junc-
tion permeability [15]. A recent study [33] identified
CLDN4 as a potent inhibitor of the invasiveness and meta-
static phenotype of pancreatic carcinoma cells by playing
role in the transforming growth factor-β and Ras/Raf signal
regulated kinase pathway. No studies to date have
reported decreased expression of CLDN4 in grade 1
breast carcinomas, in special types of breast tumour, or in
apocrine metaplasia compared with normal epithelium, as
were observed in our study. The mRNA expression of dif-
ferent CLDNs in a large number of special-type breast car-
cinomas and tumours of different grades requires
investigation so that the decrease in CLDN4 expression in
special-type breast carcinomas and IDCs of grade 1 can
be unequivocally confirmed.
Conclusion
Our observations suggest that, in breast tissue, CLDN3
expression is similar in tumours and surrounding normal tis-
sue, as demonstrated by immunohistochemistry and real-
time PCR. In contrast, absent or decreased expression of
CLDN1 in invasive breast carcinomas was demonstrated at
both mRNA and protein levels. These data suggest that
CLDN1 is involved in invasion and metastasis, and in mam-
mary carcinogenesis. Furthermore, loss of or decrease in
CLDN4 expression in grade 1 IDCs and the absence of
CLDN4 in special-type breast carcinomas and in areas of
apocrine metaplasia in benign breast tissue, as compared
with normal epithelium, suggest a role for CLDN4 in cellular
differentiation. The implications of this unique feature
require further investigation. The important issue is whether
loss of CLDN1 and CLDN4 plays a significant role in cell–
cell adhesion and tumour differentiation.
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